[Form 4] TriSalus Life Sciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. (TLSI) – Form 4 insider filing: Director William Valle reported the grant of stock options covering 15,000 common shares on 12-Jun-2025 at an exercise price of $5.50 per share. The option fully vests on the earlier of 12-Jun-2026 or the next annual shareholder meeting, conditional on continued board service. Following the award, Valle’s total beneficial holding of derivative securities (options) rose to 56,250, all held directly.
No open-market purchases, sales, or changes in non-derivative common stock were reported. The transaction is a routine director compensation item and does not alter the company’s share count or cash position.

Positive

• Incentive alignment: Grant of 15,000 at-the-money options promotes director focus on share appreciation without immediate cash expense or dilution.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine director option grant; minimal immediate market impact.

The filing discloses a standard equity-based compensation award rather than an insider purchase. Because options are granted at-the-money ($5.50) and vest over roughly one year, the event primarily aligns the director’s incentives with long-term shareholder value. There is no cash outlay by the insider and no direct dilution today; dilution would occur only if options are exercised. The increase to 56,250 total options is small relative to TriSalus’s outstanding share count, signalling neutral short-term impact for investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valle William

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$5.5	06/12/2025		A		15,000		(1)	06/11/2035	Common Stock	15,000	$0	56,250	D

Explanation of Responses:

1. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many TriSalus (TLSI) options did William Valle receive?

15,000 director stock options were granted on 12-Jun-2025.

What is the exercise price of the newly granted options?

The options can be exercised at $5.50 per share.

When do the options vest?

They fully vest on 12-Jun-2026 or on the date of the next annual shareholder meeting, whichever comes first, subject to continued service.

How many derivative securities does the director now hold in total?

Following the grant, Valle beneficially owns 56,250 options, all held directly.

Were any TriSalus common shares bought or sold in this Form 4?

No; the filing reports only an option grant, with no purchases or sales of common stock.